Bioceres: Fighting Noteholders, Foreclosure, and a Refocused Future
Amid a legal battle over Pro Farm and a strategic shift to asset-light seeds, Bioceres reports a weak quarter but signals a commitment to liquidity and simplification.
BIOX · Earnings Call · 2026-05-12
A Quarter Defined by the Courtroom
Bioceres Crop Solutions entered its fiscal third quarter 2026 with the weight of a Pro farm foreclosure auction and an escalating legal dispute hanging over every number. Revenue fell 23% to $39.4 million, gross profit dropped 30%, and adjusted EBITDA turned negative at -$0.6 million versus a positive $9.1 million a year earlier. Net loss was $10 million. The company's own litigation process now dominates its narrative, forcing management to defend its actions while simultaneously trying to preserve enterprise value.
The company strongly disputes the allegations. As explained in court filings, each of the alleged defaults turns on contested facts.
Jose Roque, General Counsel, walked investors through the November 2025 lawsuit brought by four secured noteholders, the January 2026 foreclosure auction of Pro Farm Group collateral, and the $15 million credit bid by a noteholder-affiliated entity. The company alleges the foreclosure was commercially unreasonable and is pursuing counterclaims. This is not a peripheral distraction; it has reshaped the balance sheet. CFO Ezequiel Simmermacher, in his first earnings call, detailed the $194 million reclassification of Pro Farm net assets and a $179 million non-cash loss. “Following the acceleration notice received in connection with the noteholder situation, substantially all of the related debt is currently classified as short term.” — Ezequiel Simmermacher, Chief Financial Officer · 2026-05-12
The Strategic Pivot and the New CFO
Beyond the legal turmoil, Bioceres is executing a deliberate business model transition in its seeds segment, moving away from downstream grain sales toward a more asset-light and working-capital-efficient model. Seeds and integrated products revenue plummeted 71% year-over-year, but gross margin in that segment improved from 19% to 30% on a better mix. "This transition reduced reported revenues in the near term while also lowering exposure to lower margin and more working capital-intense activity," Simmermacher explained. Crop Nutrition grew 15%, though an obsolescence adjustment related to inoculants dragged on gross profit.
The company is also managing its debt and liquidity with fresh urgency. Total financial debt stood at $229 million, with net debt of $214 million and only $14 million in cash and short-term investments. Management is advancing a reprofiling of Rizobacter debt in Argentina and exploring constructive alternatives with stakeholders. “We recognize the uncertainty generated by the ongoing litigation. While we continue to pursue the appropriate legal course and evaluate constructive alternatives where possible, our priority remains clear, stabilizing the business.” — Federico Trucco, Chief Executive Officer · 2026-05-12
The appointment of Ezequiel Simmermacher as CFO signals an intent to institutionalize financial discipline. He comes from CHS and Monsanto with a strong operational finance background. The company's focus on cash generation echoes prior calls, but the urgency is now existential. “I think, obviously, cash generation will continue to be a focus, a strong focus for us as we try to get leverage ratios back to more normal levels.” — Federico Trucco · 2025-09-09 That comment from a September 2025 call now reads as a precursor to the current crisis.
Contrast with the Broader Tape
While the global market is fixated on Batch Zero (energy auction themes) and AI infrastructure, Bioceres' story is painted in very different colors. The earnings call was sparse on macro tailwinds; instead, management acknowledged a "period of transition and operational refocusing." “This quarter reflects a period of transition and operational refocusing for the company, while it is historically our weakest quarter from a baseline business perspective.” — Federico Trucco, Chief Executive Officer · 2026-05-12
The company's own keyword trajectory shows the shift: from business model transition and strategic review in recent quarters, to the current emphasis on litigation and liquidity. The broader agInput group, including peers like constructive alternatives (a recurring phrase), is also dealing with demand softness, but none carry the legal overhang that Bioceres faces.
What changed? The company has moved past the point of merely managing a downturn; it is now fighting to preserve its existence. The strategic pivot away from grain trading is real, but the market will not reward it until the balance sheet stabilizes and the Pro Farm litigation reaches a resolution. For now, investors are staring at a small-cap (market cap ~$274 million) with a negative EBITDA quarter and a legal cloud—hardly a recipe for a re-rating, unless management can deliver on its promised liquidity and simplification initiatives.